Humanigen HGEN Stock
Humanigen Price Chart
Humanigen HGEN Financial and Trading Overview
Humanigen stock price | USD |
Previous Close | 0.16 USD |
Open | 0.16 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 1300 |
Day's Range | 0.15 - 0.16 USD |
52 Week Range | 0.09 - 3.25 USD |
Volume | 889.67K USD |
Avg. Volume | 1.11M USD |
Market Cap | 19.05M USD |
Beta (5Y Monthly) | -0.879929 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.15 USD |
HGEN Valuation Measures
Enterprise Value | 15.96M USD |
Trailing P/E | N/A |
Forward P/E | -1.7777777 |
PEG Ratio (5 yr expected) | -0.09 |
Price/Sales (ttm) | 11.214126 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 9.392 |
Enterprise Value/EBITDA | N/A |
Trading Information
Humanigen Stock Price History
Beta (5Y Monthly) | -0.879929 |
52-Week Change | -92.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.25 USD |
52 Week Low | 0.09 USD |
50-Day Moving Average | 0.16 USD |
200-Day Moving Average | 0.16 USD |
HGEN Share Statistics
Avg. Volume (3 month) | 1.11M USD |
Avg. Daily Volume (10-Days) | 1.18M USD |
Shares Outstanding | 119.08M |
Float | 110.2M |
Short Ratio | 4.06 |
% Held by Insiders | 10.51% |
% Held by Institutions | 5.87% |
Shares Short | 3.7M |
Short % of Float | 3.45% |
Short % of Shares Outstanding | 3.10% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -3061.21% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -85.049% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.7M USD |
Revenue Per Share (ttm) | 0.02 USD |
Quarterly Revenue Growth (yoy) | -78.70% |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -53634000 USD |
Diluted EPS (ttm) | -0.54 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 3.1M USD |
Total Cash Per Share (mrq) | 0.03 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.094 |
Book Value Per Share (mrq) | -0.418 |
Cash Flow Statement
Operating Cash Flow (ttm) | -64315000 USD |
Levered Free Cash Flow (ttm) | -45921500 USD |
Profile of Humanigen
Country | United States |
State | NJ |
City | Short Hills |
Address | 830 Morris Turnpike |
ZIP | 07078-2625 |
Phone | 973 200 3100 |
Website | https://www.humanigen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 6 |
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Q&A For Humanigen Stock
What is a current HGEN stock price?
Humanigen HGEN stock price today per share is USD.
How to purchase Humanigen stock?
You can buy HGEN shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Humanigen?
The stock symbol or ticker of Humanigen is HGEN.
Which industry does the Humanigen company belong to?
The Humanigen industry is Biotechnology.
How many shares does Humanigen have in circulation?
The max supply of Humanigen shares is 0.
What is Humanigen Price to Earnings Ratio (PE Ratio)?
Humanigen PE Ratio is 0.00000000 now.
What was Humanigen earnings per share over the trailing 12 months (TTM)?
Humanigen EPS is 0 USD over the trailing 12 months.
Which sector does the Humanigen company belong to?
The Humanigen sector is Healthcare.
Humanigen HGEN included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15574.35 USD — |
-0.09
|
6.67B USD — | 14784.03 USD — | 16292.28 USD — | — - | 6.67B USD — |
NASDAQ HealthCare IXHC | 863.86 USD — |
-0.68
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}